178 related articles for article (PubMed ID: 9257759)
1. Treatment of murine disseminated candidiasis with L-743,872.
Graybill JR; Najvar LK; Luther MF; Fothergill AW
Antimicrob Agents Chemother; 1997 Aug; 41(8):1775-7. PubMed ID: 9257759
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.
Abruzzo GK; Flattery AM; Gill CJ; Kong L; Smith JG; Pikounis VB; Balkovec JM; Bouffard AF; Dropinski JF; Rosen H; Kropp H; Bartizal K
Antimicrob Agents Chemother; 1997 Nov; 41(11):2333-8. PubMed ID: 9371329
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice.
Abruzzo GK; Gill CJ; Flattery AM; Kong L; Leighton C; Smith JG; Pikounis VB; Bartizal K; Rosen H
Antimicrob Agents Chemother; 2000 Sep; 44(9):2310-8. PubMed ID: 10952573
[TBL] [Abstract][Full Text] [Related]
4. Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis.
Graybill JR; Bocanegra R; Najvar LK; Hernandez S; Larsen RA
Antimicrob Agents Chemother; 2003 Jul; 47(7):2373-5. PubMed ID: 12821503
[TBL] [Abstract][Full Text] [Related]
5. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872.
Graybill JR; Bocanegra R; Luther M; Fothergill A; Rinaldi MJ
Antimicrob Agents Chemother; 1997 Sep; 41(9):1937-9. PubMed ID: 9303388
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis.
Ikeda F; Wakai Y; Matsumoto S; Maki K; Watabe E; Tawara S; Goto T; Watanabe Y; Matsumoto F; Kuwahara S
Antimicrob Agents Chemother; 2000 Mar; 44(3):614-8. PubMed ID: 10681327
[TBL] [Abstract][Full Text] [Related]
7. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis.
Hernandez S; López-Ribot JL; Najvar LK; McCarthy DI; Bocanegra R; Graybill JR
Antimicrob Agents Chemother; 2004 Apr; 48(4):1382-3. PubMed ID: 15047549
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model.
Krishnan-Natesan S; Manavathu EK; Cutright JL; Chandrasekar PH
Int J Antimicrob Agents; 2010 Jul; 36(1):33-6. PubMed ID: 20400270
[TBL] [Abstract][Full Text] [Related]
9. Caspofungin versus amphotericin B for the treatment of Candidal esophagitis.
Chocarro Martínez A; Gonzalez A; Garcia I
Clin Infect Dis; 2002 Jul; 35(1):107; author reply 107-8. PubMed ID: 12060888
[No Abstract] [Full Text] [Related]
10. Efficacies of caspofungin and a combination of caspofungin and meropenem in the treatment of murine disseminated candidiasis.
Ozcan SK; Budak F; Willke A; Filiz S; Costur P; Dalcik H
APMIS; 2006 Dec; 114(12):829-36. PubMed ID: 17207082
[TBL] [Abstract][Full Text] [Related]
11. Sequential therapy with caspofungin and fluconazole for Candida albicans infection.
Barchiesi F; Spreghini E; Baldassarri I; Marigliano A; Arzeni D; Giannini D; Scalise G
Antimicrob Agents Chemother; 2004 Oct; 48(10):4056-8. PubMed ID: 15388480
[TBL] [Abstract][Full Text] [Related]
12. Caspofungin in the treatment of oropharyngeal candidiasis.
Garbino J; Lew D; Hirschel B; Rohner P
Int J Clin Pract; 2003 Mar; 57(2):143-4. PubMed ID: 12661800
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.
Abruzzo GK; Flattery AM; Gill CJ; Kong L; Smith JG; Krupa D; Pikounis VB; Kropp H; Bartizal K
Antimicrob Agents Chemother; 1995 May; 39(5):1077-81. PubMed ID: 7625792
[TBL] [Abstract][Full Text] [Related]
14. Caspofungin versus amphotericin B for invasive candidiasis.
Brown AL; Greig JR
N Engl J Med; 2003 Mar; 348(13):1287-8; author reply 1287-8. PubMed ID: 12660396
[No Abstract] [Full Text] [Related]
15. The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans.
Wiederhold NP; Najvar LK; Fothergill AW; McCarthy DI; Bocanegra R; Olivo M; Kirkpatrick WR; Everson MP; Duncanson FP; Patterson TF
Antimicrob Agents Chemother; 2015 Jan; 59(1):690-2. PubMed ID: 25331706
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a single 6 mg/kg versus two 3 mg/kg caspofungin doses for treatment of disseminated candidiasis caused by Candida albicans in a neutropenic mouse model.
Bayegan S; Szilágyi J; Kemény-Beke Á; Földi R; Kardos G; Gesztelyi R; Juhasz B; Adnan A; Majoros L
J Chemother; 2011 Apr; 23(2):107-9. PubMed ID: 21571628
[TBL] [Abstract][Full Text] [Related]
17. Candida albicans endocarditis treatment with caspofungin in an HIV-infected patient--case report and review of literature.
Bacak V; Biocina B; Starcevic B; Gertler S; Begovac J
J Infect; 2006 Jul; 53(1):e11-4. PubMed ID: 16274746
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole.
Kartsonis N; DiNubile MJ; Bartizal K; Hicks PS; Ryan D; Sable CA
J Acquir Immune Defic Syndr; 2002 Oct; 31(2):183-7. PubMed ID: 12394797
[TBL] [Abstract][Full Text] [Related]
19. Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection.
MacCallum DM; Odds FC
Antimicrob Agents Chemother; 2004 Dec; 48(12):4911-4. PubMed ID: 15561880
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis.
Ghannoum MA; Kim HG; Long L
J Antimicrob Chemother; 2007 Mar; 59(3):556-9. PubMed ID: 17242032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
